H. Cao

发表

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.

Michael Proschan, Lori E Dodd, Jerome Pierson, 2019, The New England journal of medicine.

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Erwan L'Her, Alexander Zoufaly, Marco Massari, 2020, The New England journal of medicine.

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

R. Bruno, K. Tashima, D. Hui, 2020, The New England journal of medicine.

Adverse Events During Treatment of Multidrug-Resistant Tuberculosis: The First Cohort Event Monitoring in Vietnam

H. Cao, A. Aziz, Hoa-Mai Nguyen, 2022 .

HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico

M. Lederman, D. Podzamczer, D. Kuritzkes, 2015, Journal of the International AIDS Society.

Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib

H. Cao, S. Karovic, EF Shiuan, 2016, Clinical and translational science.

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.

K. White, M. Johnson, K. Squires, 2016, The lancet. HIV.

PREVAIL IV: A Randomized, Double-Blind, Two-Phase, Phase 2 Trial of Remdesivir versus Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors.

H. Lane, C. Reilly, L. Hensley, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor

P. German, A. Mathias, R. Humeniuk, 2021, Clinical Pharmacokinetics.

Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”

R. Humeniuk, Joy Y. Feng, H. Cao, 2021, Antimicrobial Agents and Chemotherapy.

Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial

N. Lewin-Koh, I. Rosas, N. Hanania, 2021, Intensive Care Medicine.

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

Rebecca M. Baker, Phuong Thi Tuyet Nguyen, Carol L. Eyler, 2021, The Lancet Infectious Diseases.

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial

Michael R. Wierzbicki, Tom M. Conrad, Cameron R. Wolfe, 2021, The Lancet Respiratory Medicine.

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.

O. Tsang, G. Criner, M. Mcphail, 2020, JAMA.

Compassionate Use of Remdesivir in Children With Severe COVID-19

A. Chokkalingam, M. Das, A. Camacho-González, 2021, Pediatrics.

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

Samuel M. Brown, Christina C. Chang, W. Self, 2020, The New England Journal of Medicine.

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Catharine I Paules, R. Hyzy, M. Proschan, 2022, The Lancet Respiratory Medicine.

Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results

F. Antunes, J. Gallant, J. Fehr, 2015, Journal of acquired immune deficiency syndromes.

Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects

P. German, A. Mathias, R. Humeniuk, 2020, Clinical and translational science.

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

D. Podzamczer, P. Sax, M. Saag, 2015, The Lancet.

Bioequivalence of the Rilpivirine/Emtricitabine/Tenofovir AlafenamideSingle-Tablet Regimen

B. Kearney, H. Cao, E. Quirk, 2016 .

Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data

D. Ward, R. Ebrahimi, A. Cheng, 2014, HIV clinical trials.

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

M. Saag, M. Das, J. Flamm, 2015, Journal of Acquired Immune Deficiency Syndromes.

Baseline Antiretroviral Resistance Mutations and Treatment-Emergent Resistance in HIV-1 RNA-Suppressed Patients Switching to EVG/COBI/FTC/TDF or Continuing on Their PI-, NNRTI-, or RAL-Based Regimen

K. White, H. Cao, M. Abram, 2015, Journal of acquired immune deficiency syndromes.

Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide

B. Kearney, H. Cao, J. Flaherty, 2017, Pharmacology research & perspectives.

Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels

Samuel M. Brown, Christina C. Chang, W. Self, 2021, Annals of Internal Medicine.

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

Christina C. Chang, J. Thakuria, N. Gerry, 2022, The Lancet.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women

K. Squires, C. Kityo, A. Cheng, 2018, Journal of acquired immune deficiency syndromes.

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

A. LaMarca, H. Stellbrink, F. Post, 2017, The lancet. HIV.

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

A. LaMarca, D. Podzamczer, A. Lazzarin, 2017, The lancet. HIV.

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128)

K. White, H. Cao, S. Hodder, 2017, HIV clinical trials.

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial§

J. Gallant, G. Moyle, H. Cao, 2017, Current HIV research.

Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.

Cameron K. Murray, Glenda F. Brown, Patrick B. Dorr, 2023, JAMA.

Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.

C. Kityo, V. Pokrovsky, A. Avihingsanon, 2019, Journal of acquired immune deficiency syndromes.

D. Podzamczer, P. Sax, M. Saag, 2015, The Lancet.